The Predictive Value of p53, p27Kip1, and α-Catenin for Progression in Superficial Bladder Carcinoma

European Urology

Volumn 50, Issue 1, 2006, Pages 76-82

  Schrier, Barthold Ph ^a   Vriesema, Jessica L J ^a   Witjes, J Alfred ^a   Kiemeney, Lambertus A L M ^a   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Cell adhesion complex; Cell regulatory proteins; p53; Prognosis; Urothelial cell carcinoma

Indexed keywords

ALPHA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P53;

AGE DISTRIBUTION; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ALPHA CATENIN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASM INVASIVENESS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 33744904949     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.041     Document Type: Article

References (30)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
2. Heney N.M. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 19 (1992) 429-433
3. Kiemeney L.A.L.M., Witjes J.A., Heijbroek R.P., Verbeek A.L.M., and Debruyne FM.J. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150 (1993) 60-64
4. Stein J.P., Grossfeld G.D., Ginsberg D.A., et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160 (1998) 645-659
5. Kip1. Hum Pathol 31 (2000) 751-760
6. Gontero P., Banisadr S., Frea B., and Brausi M. Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol 46 (2004) 296-311
7. TNM Classification of malignant tumors. UICC; 2002.
8. Epstein J.I., Amin M.B., Reuter V.R., and Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 24 (2000) 160-162
9. van Leenders G.J., Gage W.R., Hicks J.L., et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 162 (2003) 1529-1537
10. Tomita K., van Bokhoven A., van Leenders G.J., et al. Cadherin switching in human prostate cancer progression. Cancer Res 60 (2000) 3650-3654
11. Zlotta A.R., Noel J.C., Fayt I., et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 161 (1999) 792-798
12. Shimazui T., Schalken J.A., Giroldi L.A., et al. Prognostic value of cadherin-associated molecules (α-, β-, and γ-catenins and p120cas) in bladder tumors. Cancer Res 56 (1996) 4154-4158
13. Vriesema J.L., Aben K.K., Witjes J.A., Kiemeney L.A., and Schalken J.A. Superficial and metachronous invasive bladder carcinomas are clonally related. Int J Cancer 93 (2001) 699-702
14. Schrier B.P.h., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A.L.M., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: Difference between primary and progressive tumors and implications for therapy. Eur Urol 45 (2004) 292-296
15. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular anti-mitogenic signals. Cell 78 (1994) 59-66
16. Kip1 is expressed preferentially in early stages of urothelial carcinoma. Urology 56 (2000) 689-695
17. Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 84 (2001) 1242-1251
18. Smith N.D., Rubenstein J.N., Eggener S.E., and Kozlowski J.M. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 169 (2003) 1219-1228
19. Holmäng S., Andius P., Hedelin H., Wester K., Busch C., and Johnasson S.L. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 165 (2001) 1124-1128 discussion 1128-30
20. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear over-expression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Nat Cancer Inst 6 (1993) 53-59
21. Hollstein M., Sidransky D., Volgelstein B., and Harris C.C. p53 Mutations in human cancers. Science 253 (1991) 49-53
22. Finlay C.A., Hinds P.W., Tan T.H., Eliyahu D., Oren M., and Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms hsc70-p53 complex with an altered half-life. Mol Cell Biol 8 (1988) 531-539
23. Yoshimura I., Kudoh J., Sato S., Tazaki H., and Sinizu N. p53 gene mutation in recurrent superficial bladder cancer. J Urol 153 (1995) 1711-1715
24. Vet J.A.M., Bringuier P.P., Schaafsma H.E., Witjes J.A., Debruyne F.M.J., and Schalken J.A. Comparison of p53 protein over expression with p53 mutation in bladder cancer: clinical and biological aspects. Lab Invest 73 (1995) 837-843
25. Hall P.A., and Lane D.P. p53 in tumor pathology: can we trust immunohistochemistry? Revised! [editorial]. J Pathol 172 (1994) 1-4
26. Wynford T.D. p53 In tumor pathology: can we trust immunohistochemistry? [editorial]. J Pathol 166 (1992) 329-330
27. Syrigos K.N., Harrington K.J., and Pignatelli M. Role of adhesion molecules in bladder cancer: an important part of the jigsaw. Urology 53 (1999) 428-434
28. Shimazui T., Schalken J.A., Giroldi L.A., et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 56 (1996) 4154-4158
29. Kiemeney L.A.L.M., Witjes J.A., Heijbroek R.P., Verbeek A.L.M., and Debruyne F.M.J. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150 (1993) 60-64
30. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer patients using EORTC risk tables. Eur Urol 49 (2006) 466-477